Crossmark

HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis

Crossref DOI link: https://doi.org/10.1186/s42466-019-0024-2

Published Online: 2019-06-20

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Seidel, Sabine https://orcid.org/0000-0002-1671-3297
Korfel, Agnieszka

Kowalski, Thomas

Margold, Michelle

Ismail, Fatme

Schroers, Roland

Baraniskin, Alexander

Pels, Hendrik

Martus, Peter

Schlegel, Uwe
License Information

Text and Data Mining valid from 2019-06-20

Version of Record valid from 2019-06-20
More Information

Article History

Received: 29 March 2019

Accepted: 26 April 2019

First Online: 20 June 2019

Ethics approval and consent to participate

: As this was a retrospective analysis on data obtained from the archives of the clinic no written informed consent was obtained. The ethics committee of faculty of medicine of the University of Bochum approved the study (reference number 18–6472).

: Not applicable.

: U.S. has received honoraria as a speaker from Novartis, GSK, medac and as an Advisory Board member from Roche and Optune. M.M. has received an SIO grant from medac.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below